-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

The FIRST and ONLY Therapy Approved for Adults with Indolent Systemic Mastocystosis (ISM)

Sponsor: Blueprint Medicines
Program: Product Theaters
Saturday, December 9, 2023: 11:30 AM-12:30 PM
Room 4 (San Diego Convention Center)
Daniel Shaheen, Blueprint Medicines
No relevant conflicts of interest to declare.
For In-Person Participants Only
See more of: Product Theaters